Cid2858522

Manufactured by Bio-Techne

Sourced in United States, United Kingdom

CID2858522 is a lab equipment product manufactured by Bio-Techne. It is designed for laboratory use, but a detailed description of its core function is not available at this time.

Automatically generated - may contain errors

Lab products found in correlation

Tnf α, by Cell Signaling Technology (1 mentions) Epidermal growth factor (egf), by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Cardamonin, by Bio-Techne (1 mentions) Luteolin, by Selleck Chemicals (1 mentions) Bay11 7085, by Selleck Chemicals (1 mentions) Tpca 1, by Selleck Chemicals (1 mentions) Ikk 16, by Selleck Chemicals (1 mentions) Pictilisib, by Selleck Chemicals (1 mentions) Costunolide, by Bio-Techne (1 mentions) Cgs 21680 hcl, by Bio-Techne (1 mentions) Ro 106 9920, by Bio-Techne (1 mentions) Andrographolide, by Selleck Chemicals (1 mentions) Celastrol, by Bio-Techne (1 mentions) Imd0354, by Bio-Techne (1 mentions) Pf184, by Bio-Techne (1 mentions) Betulinic acid, by Selleck Chemicals (1 mentions) Tnf α, by Thermo Fisher Scientific (1 mentions) Bay11 7082, by Selleck Chemicals (1 mentions) Mk 2206, by Santa Cruz Biotechnology (1 mentions)

3 protocols using cid2858522

EGF and TNFα Signaling Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

DK-MG cells were seeded in 6-well plates at 2×10⁵ cells per well for western blot analysis or at 4×10⁴ cells per well for real-time observation, incubated overnight to allow for adhesion and serum starved for subsequent 24h. Serum free medium containing appropriate inhibitors was applied onto cells and incubated for indicated amount of time, prior to stimulation with 20ng/mL EGF (Sigma-Aldrich) or 5ng/mL TNFa (Cell Signaling Technology) for 20 or 30min, as indicated, prior to lysis for western blotting or left for real-time observation. Following concentrations of inhibitors were used: DMSO (Sigma, Cat. No.D2438, solvent control), 10 μM Erlotinib (Molecula; Cat. No. 89983631), 2.5 μM ACHP (Tocris Bioscience, Cat. No. 4547), 1 μM CID2858522 (Tocris Bioscience, Cat. No. 4246).

Stec W.J., Rosiak K., Siejka P., Peciak J., Popeda M., Banaszczyk M., Pawlowska R., Treda C., Hulas-Bigoszewska K., Piaskowski S., Stoczynska-Fidelus E, & Rieske P. (2016). Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. Oncotarget, 7(22), 31907-31925.

+ Open protocol

+ Expand

Evaluating NF-κB Modulators in Cell Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

NF-κB antagonist and agonists: TNFα (315–01A, Peprotech, Rocky Hill, NJ, USA ), Prostratin (5739, Tocris, Bristol, UK), CGS 21680 HCl (1063, Tocris), Betulinic acid (53603, Selleck Chemicals, Houston, TX, USA), PSI (4045, Tocris), Cardamonin (2509, Tocris), Bay 11–7082 (S2913, Selleck Chemicals), Bay 11–7085 (S7352, Selleck Chemicals), RO 106–9920 (1778, Tocris), TPCA-1 (S2824, Selleck Chemicals), Ikk-16 (S2882, Selleck Chemicals), PF 184 (4238, Tocris), IMD 0354 (2483, Tocris), Andrographolide (S2261, Selleck Chemicals), Costunolide (2483, Tocris), CID 2858522 (4246, Tocris), Pictilisib (S1065, Selleck Chemicals), Luteolin (S2320, Selleck Chemicals), Celastrol (1571, Tocris), Artemisinin (2668, Tocris). Cells were plated (at a seeding density of 1x10⁴ for 96 well plates and 1x10³ for 384 well plates) 12 h before treatment. Cells were treated with drugs at a range of concentrations either with fresh media (for agonists and vehicle only control) or fresh media with 5ng/ml TNFα (for antagonists and vehicle control) and incubated for 24 h. Each drug dose was performed in triplicate or quadruplicate and experiments were repeated at least three times.

Harrold A.P., Cleary M.M., Bharathy N., Lathara M., Berlow N.E., Foreman N.K., Donson A.M., Amani V., Zuercher W.J, & Keller C. (2020). In vitro benchmarking of NF-κB inhibitors. European journal of pharmacology, 873, 172981.

+ Open protocol

+ Expand

Modulation of DFC Differentiation by PKC, Akt, and NF-κB

Check if the same lab product or an alternative is used in the 5 most similar protocols

For examining the role of classical PKCs on the differentiation of DFCs, the cells were treated with 100 nM specific inhibitor Gö 6976 (Tocris) in addition to the media. To study the role of Akt, DFCs were treated with 10 μM Akt activator SC-79 (Sigma-Aldrich) or 200 nM Akt inhibitor MK-2206 (Santa Cruz Biotechnology, Dallas, USA). Besides, NF-κB was stimulated by supplementation of media with 200 nM phorbol 12-myristate 13-acetate (PMA) (Abcam, Cambridge, UK), which activates NF-κB via PKC, or inhibited with up to 500 nM (concentrations as indicated in figure legends) ACHP as general NF-κB inhibitor or CID2858522 as specific inhibitor of PKC-dependent NF-κB activation (both Tocris). All chemicals were dissolved in dimethyl sulfoxide (DMSO) and diluted in differentiation or control medium.

Pieles O., Reichert T.E, & Morsczeck C. (2021). Classical isoforms of protein kinase C (PKC) and Akt regulate the osteogenic differentiation of human dental follicle cells via both β-catenin and NF-κB. Stem Cell Research & Therapy, 12, 242.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!